PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsTwo-drug approach could offer hope to ovarian cancer patients

BioNews

Two-drug approach could offer hope to ovarian cancer patients

Published 24 September 2021 posted in News and appears in BioNews 1114

Author

Jen Willows

Legal Editor
PET BioNews

A clinical trial combining two cancer therapies has shown promising results in patients with low grade serous ovarian cancer...

A clinical trial combining two cancer therapies has shown promising results in patients with low grade serous ovarian cancer.

In the Phase 1 study run by the Institute of Cancer Research (ICR) and the Royal Marsden Hospital, both in London, the drug combination prevented patients' cancers from progressing for just under two years on average. Of 24 patients who took part, 46 percent saw their tumours shrink significantly and the proportion was higher (64 percent) in patients with a mutation in the KRAS gene.

'I am delighted that this drug combination has worked so well in a group of patients who are in urgent need of new treatments said Dr Susana Banerjee, research lead for the Royal Marsden's gynaecology unit. 'If these findings are confirmed in larger trials, they'll represent a significant advance in low-grade serous ovarian cancer treatment.'

Low grade serous ovarian cancer is a rare, slow-growing form of the disease. On average it presents in younger patients than other types of ovarian cancer and often responds poorly to chemotherapy and hormone-based treatments.

The two drugs used in the trial are defactinib, a FAK inhibitor and an RAF/MEK inhibitor called VS-6766. Each of these inhibits signalling molecules in pathways associated with cell survival, proliferation and migration.

KRAS is a known oncogene, and mutated variants are found in many cancers. KRAS mutations are difficult to target with drugs, but the RAF/MEK targets are involved in the same pathway. For this reason, MEK inhibitors had already shown promise in treating low grade serous ovarian cancer but tumours would quickly develop resistance.

Adding a FAK inhibitor made it much harder for the tumour to evolve resistance, and the approach was successful even in patients who had been treated with a MEK inhibitor before joining the study.

'Scientists have been working to develop treatments that can effectively target KRAS-driven cancers for decades,' said ICR chief executive Professor Kristian Helin. 'This study has turned a deep understanding of how cancer fuels its growth and develops resistance into a highly targeted treatment for patients who currently have few treatment options.'

Sources and References

  • 19/09/2021
    Guardian
    Highly effective' ovarian cancer treatment could help thousands of women
  • 19/09/2021
    Institute of Cancer Research
    Drug combination shows promise in treatment-resistant advanced ovarian cancer
  • 24/09/2021
    Oncology Pro
    25MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
  • 20/09/2021
    PharmaTimes
    Promising early results for new ovarian cancer drug combo

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 December 2021 • 2 minutes read

FANCI gene mutation more common in ovarian cancer patients

by Francesca Gavins

Mutations in the FANCI gene have been linked to risks of ovarian cancer for the first time...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 May 2021 • 2 minutes read

PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations

by Emma Bunting

New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...

PET BioNews
News
23 April 2021 • 2 minutes read

Olaparib extends life of ovarian cancer patients with BRCA1/2

by Hannah Flynn

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Artificial mitochondria generate energy and save damaged cells

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856